

# AZURE HEALTH TECHNOLOGY LIMITED

---

27 April 2020

ASX Markets Announcements  
Australian Securities Exchange  
Level 40, Central Park, 152-158 St Georges Terrace,  
Perth WA 6000

## WITHDRAWAL OF REINSTATEMENT APPLICATION

Azure Health Technology Limited (ASX: AZT) (**AZT** or **Company**) advises that the Directors have resolved to withdraw AZT's application for reinstatement to the official list of ASX. The Company was unable to satisfy the spread condition in ASX Listing Rule 1.1 Condition 8 (300 shareholders holding a parcel of shares with a value of at least \$2,000).

The offer made under the Replacement Prospectus dated 12 February 2020 (as supplemented by the First Supplementary Prospectus dated 9 April 2020 (**Offer**) closed on Friday 17 April 2020. In view of the Directors resolving to withdraw AZT's application for reinstatement to the official list of ASX the listing condition contained in the Prospectus will not be satisfied and the Company is required to comply with section 724 of the Corporations Act 2001.

Investors who have applied for and paid for shares under the Offer will have their application monies refunded in full.


The Company has lodged a Second Supplementary Prospectus with ASIC today 27 April 2020. The Second Supplementary Prospectus will be issued as an electronic prospectus. A copy can be downloaded from the Company's website at [www.azureht.com.au](http://www.azureht.com.au). and is attached to this announcement.

The Company's Share Registry, Link Market Services, will contact each investor who has applied for and paid for shares under the Offer and arrange to repay the money received from them.

Anyone with questions concerning the refund can contact the Share Registry on 1800 262 299 or the Company on 0414 906 611.

The Company expects to be delisted from the official list of ASX on Friday 1 May 2020.

Please direct any queries to the Company Secretary Greg Starr at [starr@azureht.com.au](mailto:starr@azureht.com.au).



Gregory Starr  
**DIRECTOR**

# SUPPLEMENTARY PROSPECTUS

## AZURE HEALTH TECHNOLOGY LIMITED ACN 111 082 485

### 1. IMPORTANT INFORMATION

This is the second supplementary prospectus (**Second Supplementary Prospectus**) intended to be read with the replacement prospectus dated 12 February 2020 (**Prospectus**) which is supplemented by the first supplementary prospectus dated 9 April 2020 (**First Supplementary Prospectus**), in each case issued by Azure Health Technology Limited ACN 111 082 485 (**Company**).

This Second Supplementary Prospectus is dated 27 April 2020 and was lodged with ASIC on that date. ASIC, ASX and their respective officers take no responsibility for the contents of this Second Supplementary Prospectus.

This Second Supplementary Prospectus should be read together with the Prospectus and the First Supplementary Prospectus. Other than as set out below, all details in relation to the Prospectus and the First Supplementary Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus and the First Supplementary Prospectus have the same meaning when used in this Second Supplementary Prospectus. If there is a conflict between the Prospectus, the First Supplementary Prospectus and this Second Supplementary Prospectus, this Second Supplementary Prospectus will prevail.

This Second Supplementary Prospectus will be issued with the Prospectus and the First Supplementary Prospectus as an electronic prospectus, copies of which can be downloaded from the website of the Company at [www.azureht.com.au](http://www.azureht.com.au).

This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisors without delay.

### 2. WITHDRAWAL OF REINSTATEMENT APPLICATION

The purpose of this Second Supplementary Prospectus is to notify investors that the Company has resolved to withdraw the Company's application for reinstatement to the official list of ASX.

In view of the Directors resolving to withdraw the Company's application for reinstatement to the official list of ASX the listing condition contained in the Prospectus and the First Supplementary Prospectus will not be satisfied and the Company is required to comply with section 724 of the Corporations Act 2001.

Investors who have applied for and paid for shares under the Offer will have their application monies refunded in full.

The Company advises that the Offer is now closed and that the timetable for the Offer is no longer in effect. The expiry date of the Prospectus (as supplemented by the First Supplementary Prospectus) is brought forward to the date of this Second Supplementary Prospectus, being 27 April 2020.

### 3. REFUND OF APPLICATION MONIES

All Application Monies received by the Company pursuant to the Prospectus will be refunded in full.

Application Monies received from clients of the Lead Manager, Viriathus Capital, will be refunded by the Lead Manager as soon as practicable.

For those applicants who subscribed for Shares under the Prospectus directly through the Company's Share Registry, Link Market Services, payment of the refund will be made to the account recorded on the share register. If no account is in place, these applicants will be contacted by the Company/Share Registry and asked to provide their bank details to the Company/Share Registry. If bank details are not provided the Company/Share Registry will refund those Application Monies by way of cheque to the address set out in the applicant's Application Form.

The Company will coordinate with the Share Registry to process all cheques and bank transfers as soon as practicable.


Anyone with questions concerning the refund can contact the Company on 0414 906 611 or the Share Registry on 1800 262 299.

#### **4. DIRECTORS' AUTHORISATION**

This Second Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors. The Directors believe that the Prospectus when read together with this Second Supplementary Prospectus contains all the information that would be required by sections 710 and 711 of the Corporations Act and does not contain any material statement that is misleading or deceptive.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Second Supplementary Prospectus with ASIC and has not withdrawn that consent prior to lodgement.

Dated 27 April 2020

A handwritten signature in dark ink, appearing to be 'Greg Starr', with a large loop at the start and a wavy line extending to the right.

**Greg Starr**  
**Director**